| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Direct reprogramming is expected to be developed as a curative therapy for diseases of organs and cells that do not retain the ability to regenerate on their own. Although there have been reports on the conversion of β cells to functional glucose-responsive cells by direct reprogramming as a curative therapy, the creation of functional β cells has not yet been achieved. The search for and analysis of new differentiation factors are necessary for the differentiation conversion to functionally mature β-cells. To elucidate a part of the process of functional maturation of β cells, we verified the function of ACT-SC reporter cells used for temporal gene expression analysis, and obtained unexpected results in transgene expression in specific safety regions.
|
